Cancer Vaccine Partnering Agreements
02-Apr-2012 | News-Press Release
The Cancer Vaccine Partnering Agreements report provides an understanding and  access to the cancer vaccine partnering deals and agreements entered into by the  worlds leading healthcare companies.
  
  * Trends in cancer vaccine partnering deals
  * Disclosed headlines, upfronts, milestones and royalties by stage of  development
  * Cancer vaccine partnering contract documents
  * Top cancer vaccine deals by value
  http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/cancer-vaccine-partnering-agreements.html
  
  Description
  The Cancer Vaccine Partnering Agreements report provides an understanding  and access to the cancer vaccine partnering deals and agreements entered into by  the worlds leading healthcare companies.  Market Research Book
  
  The report provides an understanding and analysis of how and why companies enter  cancer vaccine partnering deals. The majority of deals are discovery or  development stage whereby the licensee obtains a right or an option right to  license the licensors vaccine technology. These deals tend to be multicomponent,  starting with collaborative R&D, and commercialization of outcomes. The report  also includes adjuvant deals and alliances.
  
  Understanding the flexibility of a prospective partner’s negotiated deals terms  provides critical insight into the negotiation process in terms of what you can  expect to achieve during the negotiation of terms. Whilst many smaller companies  will be seeking details of the payments clauses, the devil is in the detail in  terms of how payments are triggered – contract documents provide this insight  where press releases do not.
  
  This report contains over 150 links to online copies of actual cancer vaccine  deals and where available, contract documents as submitted to the Securities  Exchange Commission by companies and their partners. Contract documents provide  the answers to numerous questions about a prospective partner’s flexibility on a  wide range of important issues, many of which will have a significant impact on  each party’s ability to derive value from the deal.
  
  The initial chapters of this report provide an orientation of cancer vaccine  dealmaking and business activities.
  
  Chapter 1 provides an introduction to the report, whilst chapter 2 provides an  overview of the trends in cancer vaccine dealmaking since 2007, including  details of disclosed headline, upfront, milestone and royalty terms.
  
  Chapter 3 provides a review of the leading cancer vaccine deals since 2007.  Deals are listed by headline value. Where the deal has an agreement contract  published at the SEC a link provides online access to the contract.
  
  Chapter 4 provides a comprehensive and detailed review of cancer vaccine  partnering deals signed and announced since 2007, and where available, a  contract document is available in the public domain. The chapter
  is organized by company A-Z, stage of development at signing, deal type  (collaborative R&D, co-promotion, licensing etc), and specific oncology therapy  focus. Each deal title links via Weblink to an online version of the deal record  and where available, the contract document, providing easy access to each  contract document on demand.
  
  The report also includes numerous tables and figures that illustrate the trends  and activities in cancer vaccine partnering and dealmaking since 2007.
  
  In conclusion, this report provides everything a prospective dealmaker needs to  know about partnering in the research, development and commercialization of  cancer vaccine technologies and products.
  
  Report scope
  Cancer Vaccine Partnering Agreements is intended to provide the reader with  an in-depth understanding and access to cancer vaccine trends and structure of  deals entered into by leading companies worldwide.
  
  Cancer Vaccine Partnering Agreements includes:
  * Trends in cancer vaccine dealmaking in the biopharma industry since 2007
  * Analysis of cancer vaccine deal structure
  * Access to headline, upfront, milestone and royalty data
  * Access to over 150 cancer vaccine deal records
  * The leading cancer vaccine deals by value since 2007
  * Includes adjuvant and drug delivery deals and alliances since 2007
  
  In Cancer Vaccine Partnering Agreements, the available deals are listed by:
  * Company A-Z
  * Headline value
  * Stage of development at signing
  * Deal component type
  * Specific oncology therapy target
  
  Each deal title links via Weblink to an online version of the deal record and  where available, the contract document, providing easy access to each contract  document on demand.
  
  For more information kindly visit : 
  Cancer Vaccine Partnering Agreements
  
  Or
  
  Bharat Book Bureau
  Tel: +91 22 27810772 / 27810773
  Fax: + 91 22 27812290
  Email: info@bharatbook.com
  Website: www.bharatbook.com
  Follow us on twitter:  http://twitter.com/#!/Sandhya3B
This release was submitted by a Newsbox user.
Any communication related to the content of this release should be sent to the release submitter.
Author Info
Tag Cloud
Categories
More Releases
- Research on Global and China Epoxy Resin Industry Chain Report
 - The Geothermal Energy Market 2012-2022
 - Adhesives and Sealants: Global Markets
 - Dermatological Drugs: World Market Prospects 2012-2022
 - The Electric and Range Extended Electric Light-Vehicle Report
 - India Urban & Industrial Waste to Energy Market
 - Understanding Russia's Regional Health Markets
 - 2012 Deep Research Report on China Wind Bearing Industry
 - Top 1000 Advertising Agents (European)
 - HNWI Asset Allocation in Switzerland to 2016
 
		


